Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 235, doi. 10.1007/s11523-008-0093-6
- By:
- Publication type:
- Article
Works matching IS 17762596 AND DT 2008 AND VI 3 AND IP 4
Results: 7
1
2
Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 253, doi. 10.1007/s11523-008-0094-5
- By:
- Publication type:
- Article
3
Functional inactivation of CD4+CD25<sup>high</sup> regulatory T cells using low dose human/mouse chimeric anti-CD25 monoclonal antibody enhanced lymphokine-activated killer cells activity.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 227, doi. 10.1007/s11523-008-0095-4
- By:
- Publication type:
- Article
4
Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
5
Plasma cell leukemia: advantages of treatment with bortezomib.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 265, doi. 10.1007/s11523-008-0096-3
- By:
- Publication type:
- Article
6
Management of skin toxicity of epidermal growth factor receptor inhibitors.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 245, doi. 10.1007/s11523-008-0092-7
- By:
- Publication type:
- Article
7
Successful treatment of brain metastases from renal cell cancer using radiotherapy in combination with sorafenib.
- Published in:
- Targeted Oncology, 2008, v. 3, n. 4, p. 259, doi. 10.1007/s11523-008-0091-8
- By:
- Publication type:
- Article